R Ryan
Janssen Pharmaceutica
8 Papers
47 Citations
R Ryan is an academic researcher from Janssen Pharmaceutica. The author has contributed to research in topics: Simeprevir & Darunavir. The author has an hindex of 5, co-authored 8 publications.
Chat about Author
Papers
Effects of once-daily darunavir/ritonavir versus atazanavir/ritonavir on insulin sensitivity in HIV-infected persons over 48 weeks: results of an exploratory substudy of METABOLIK, a phase 4, randomized trial.
Edgar T. Overton,Pablo Tebas,Bruce Coate,R Ryan,Amy Perniciaro,Yaswant K. Dayaram,Guy De La Rosa,Bryan Baugh +7 more
TL;DR: The effects of DRV/r versus ATV/ r on insulin sensitivity over 48 weeks were compared using the euglycemic hyperinsulinemic clamp, the preferred method to assess insulin sensitivity.
19
Efficacy and safety of simeprevir and sofosbuvir with and without ribavirin in subjects with recurrent genotype 1 hepatitis C postorthotopic liver transplant: the randomized GALAXY study
Jacqueline G. O'Leary,Robert J. Fontana,Kimberly A. Brown,James R. Burton,Roberto J. Firpi-Morell,Andrew J. Muir,Christopher B. O'Brien,Mordechai Rabinovitz,K. Rajender Reddy,R Ryan,Adam Shprecher,Shirley Villadiego,Avinash Prabhakar,Robert S. Brown +13 more
TL;DR: This prospective, randomized, phase 2 study in subjects with recurrent hepatitis C virus (HCV) genotype 1 postorthotopic liver transplant evaluated once‐daily simeprevir + sofosbuvir treatment, with or without ribavirin, was efficacious and well tolerated.
16
The Intelence aNd pRezista Once A Day Study (INROADS): a multicentre, single-arm, open-label study of etravirine and darunavir/ritonavir as dual therapy in HIV-1-infected early treatment-experienced subjects.
PJ Ruane,Cynthia Brinson,M Ramgopal,R Ryan,Bruce Coate,M Cho,Thomas N. Kakuda,David E. Anderson +7 more
TL;DR: The nucleoside‐sparing regimen of etravirine 400 mg with darunavir/ritonavir 800/100mg once‐daily in HIV‐1‐infected treatment‐experienced subjects or treatment‐naïve subjects with transmitted resistance is evaluated.
14
Pharmacokinetics of Total and Unbound Etravirine in HIV-1-Infected Pregnant Women.
Moti Ramgopal,Olayemi Osiyemi,Carmen D. Zorrilla,Herta Crauwels,R Ryan,Kimberley Brown,Vera Hillewaert,Bryan Baugh +7 more
TL;DR: Etravirine 200 mg twice daily, as part of individualized combination antiretroviral therapy, may be a treatment option for HIV-1–infected pregnant women.
13
Efficacy and Safety of Simeprevir and Sofosbuvir with and without Ribavirin for 12 Weeks in Subjects with Recurrent Genotype 1 Hepatitis C Post-Orthotopic Liver Transplant: The Galaxy Study
Jeanne O’Leary,Kimberly A. Brown,James R. Burton,Roberto J. Firpi-Morell,Robert J. Fontana,Andrew J. Muir,Christopher B. O'Brien,Mordechai Rabinovitz,K. Rajender Reddy,R Ryan,Adam Shprecher,Shirley Villadiego,Avinash Prabhakar,Robert S. Brown +13 more
5